So Hee Kang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
So Hee Kang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Hong Ju Park
Department of Otorhinolaryngology-Head and Neck Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
1 shared publication - Hye Ah Joo
Department of Otorhinolaryngology-Head and Neck Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
1 shared publication - Jong Woo Chung
Department of Otorhinolaryngology-Head and Neck Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
1 shared publication - Joong Ho Ahn
Department of Otorhinolaryngology-Head and Neck Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
1 shared publication - Jun-Pyo Myong
Department of Occupational and Environmental Medicine, Seoul St. Mary’s Hospital, College of Medicine, the Catholic University of Korea, Seoul, Republic of Korea
1 shared publication - Min Young Kwak
Department of Otorhinolaryngology-Head and Neck Surgery, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong-si
1 shared publication
Latest Publications
- Open Access
- 31 July 2026
- Published by Korean Rhinologic Society in Journal of Rhinology
- Vol. 33 (2) , 126-130
A Huge Intraosseous Hemangioma in the Maxillary Sinus Misdiagnosed as Osteosarcoma: A Case Report
Intraosseous hemangiomas are rare benign vascular tumors that account for less than 1% of all bone tumors and are exceptionally uncommon in the sinonasal region. Their aggressive-appearing radiological features may mimic those of malignant bone tumors, creating diagnostic challenges. An 18-year-old man presented with right-sided nasal obstruction and epistaxis. Imaging revealed a large destructive mass in the right maxillary sinus that was suspicious for malignancy, including osteosarcoma. Endoscopic biopsy showed nonspecific benign osseous features that were discordant with the radiological findings. For this reason, endoscopic medial maxillectomy was performed. Histopathological examination with CD31 and CD34 immunostaining confirmed intraosseous venous hemangioma. Intraosseous hemangioma should be considered in the differential diagnosis of aggressive-appearing sinonasal masses, especially when imaging and biopsy findings are discordant, as its recognition may help prevent unnecessarily aggressive treatment.
- 31 July 2026
- Published by Korean Rhinologic Society in Journal of Rhinology
- Vol. 33 (2) , 126-130
Open AccessA Huge Intraosseous Hemangioma in the Maxillary Sinus Misdiagnosed as Osteosarcoma: A Case Report
Intraosseous hemangiomas are rare benign vascular tumors that account for less than 1% of all bone tumors and are exceptionally uncommon in the sinonasal region. Their aggressive-appearing radiological features may mimic those of malignant bone tumors, creating diagnostic challenges. An 18-year-old man presented with right-sided nasal obstruction and epistaxis. Imaging revealed a large destructive mass in the right maxillary sinus that was suspicious for malignancy, including osteosarcoma. Endoscopic biopsy showed nonspecific benign osseous features that were discordant with the radiological findings. For this reason, endoscopic medial maxillectomy was performed. Histopathological examination with CD31 and CD34 immunostaining confirmed intraosseous venous hemangioma. Intraosseous hemangioma should be considered in the differential diagnosis of aggressive-appearing sinonasal masses, especially when imaging and biopsy findings are discordant, as its recognition may help prevent unnecessarily aggressive treatment.
- Open Access
- 20 July 2025
- Published by The Korean Audiological Society in Journal of Audiology and Otology
- Vol. 29 (3) , 191-196
Impact of Hyperbaric Oxygen Therapy on Recovery in Patients With Sudden Sensorineural Hearing Loss: An Observational Study
Background and Objectives: We aimed to assess the efficacy of various treatments for patients experiencing sudden sensorineural hearing loss (SSNHL), with a focus on hyperbaric oxygen therapy (HBOT) and the effect of HBOT administration timing on hearing recovery.Subjects and Methods: In keeping with guideline recommendations, patients with SSNHL enrolled in this study received systemic corticosteroids, intratympanic dexamethasone, or HBOT in combination or as monotherapy. Hearing thresholds were determined using pure-tone audiometry (dB HL), and recovery was categorized as complete recovery (CR), partial recovery (PR), slight recovery (SR), or no recovery (NR). Post-treatment thresholds were assessed 2-3 months after symptom onset.Results: After treatment, we observed CR in 16 patients (15.2%), PR in 22 patients (21.0%), SR in 44 patients (42.0%), and NR in 23 patients (22.0%). Notably, among the 79 patients with severe hearing loss (>70 dB), those who received treatment within 2 weeks of onset showed better hearing outcomes than those who started treatment after 2 weeks. In the HBOT group, a shorter interval between symptom onset and HBOT initiation was associated with a higher likelihood of hearing improvement. Importantly, in patients with an initial hearing threshold of <70 dB, initiating HBOT within 2 weeks was associated with statistically significantly higher hearing recovery rates.Conclusions: The findings of our study support the premise that early initiation of HBOT within 2 weeks of symptom onset results in better hearing recovery in patients with SSNHL.
- 20 July 2025
- Published by The Korean Audiological Society in Journal of Audiology and Otology
- Vol. 29 (3) , 191-196
Open AccessImpact of Hyperbaric Oxygen Therapy on Recovery in Patients With Sudden Sensorineural Hearing Loss: An Observational Study
Background and Objectives: We aimed to assess the efficacy of various treatments for patients experiencing sudden sensorineural hearing loss (SSNHL), with a focus on hyperbaric oxygen therapy (HBOT) and the effect of HBOT administration timing on hearing recovery.Subjects and Methods: In keeping with guideline recommendations, patients with SSNHL enrolled in this study received systemic corticosteroids, intratympanic dexamethasone, or HBOT in combination or as monotherapy. Hearing thresholds were determined using pure-tone audiometry (dB HL), and recovery was categorized as complete recovery (CR), partial recovery (PR), slight recovery (SR), or no recovery (NR). Post-treatment thresholds were assessed 2-3 months after symptom onset.Results: After treatment, we observed CR in 16 patients (15.2%), PR in 22 patients (21.0%), SR in 44 patients (42.0%), and NR in 23 patients (22.0%). Notably, among the 79 patients with severe hearing loss (>70 dB), those who received treatment within 2 weeks of onset showed better hearing outcomes than those who started treatment after 2 weeks. In the HBOT group, a shorter interval between symptom onset and HBOT initiation was associated with a higher likelihood of hearing improvement. Importantly, in patients with an initial hearing threshold of <70 dB, initiating HBOT within 2 weeks was associated with statistically significantly higher hearing recovery rates.Conclusions: The findings of our study support the premise that early initiation of HBOT within 2 weeks of symptom onset results in better hearing recovery in patients with SSNHL.
- Open Access
- 15 October 2024
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 56 (4) , 1077-1083
The Impact of Infectious Mononucleosis History on the Risk of Developing Lymphoma and Nasopharyngeal Carcinoma: A Retrospective Large-Scale Cohort Study Using National Health Insurance Data in South Korea
Purpose This study aimed to assess the long-term risks associated with a history of infectious mononucleosis (IM), primarily caused by the Epstein-Barr virus (EBV). Specifically analyzing the potential increase in developing nasopharyngeal cancer (NPC) and lymphoma in patients with a history of IM and exploring the prevalence of other EBV-associated conditions.Materials and Methods The Korean National Health Insurance Service (NHIS) database was utilized for a retrospective analysis, covering data from 2002 to 2021. A total of 25,582 IM patients and controls were included, with 1:1 propensity score matching. The study monitored outcomes, including lymphoma, NPC, gastric cancer, multiple sclerosis, and all-cause mortality.Results Patients with a history of IM demonstrated a significantly higher incidence of lymphoma (hazard ratio [HR], 5.320; 95% confidence interval [CI], 3.208 to 8.820; p < 0.001) and NPC (HR, 7.116; 95% CI, 1.617 to 31.314; p=0.009) during the follow-up period compared with the control group. Additionally, the IM group showed an increased rate of all-cause mortality (HR, 2.225; 95% CI, 1.858 to 2.663; p < 0.001).Conclusion This study suggests that individuals with a history of IM have an elevated risk of developing lymphoma and NPC in South Korea, emphasizing the importance of vigilant follow-up and monitoring. The results advocate for heightened awareness and potential national monitoring policies to address the long-term health implications of EBV infection and to implement preventive measures.
- 15 October 2024
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 56 (4) , 1077-1083
Open AccessThe Impact of Infectious Mononucleosis History on the Risk of Developing Lymphoma and Nasopharyngeal Carcinoma: A Retrospective Large-Scale Cohort Study Using National Health Insurance Data in South Korea
Purpose This study aimed to assess the long-term risks associated with a history of infectious mononucleosis (IM), primarily caused by the Epstein-Barr virus (EBV). Specifically analyzing the potential increase in developing nasopharyngeal cancer (NPC) and lymphoma in patients with a history of IM and exploring the prevalence of other EBV-associated conditions.Materials and Methods The Korean National Health Insurance Service (NHIS) database was utilized for a retrospective analysis, covering data from 2002 to 2021. A total of 25,582 IM patients and controls were included, with 1:1 propensity score matching. The study monitored outcomes, including lymphoma, NPC, gastric cancer, multiple sclerosis, and all-cause mortality.Results Patients with a history of IM demonstrated a significantly higher incidence of lymphoma (hazard ratio [HR], 5.320; 95% confidence interval [CI], 3.208 to 8.820; p < 0.001) and NPC (HR, 7.116; 95% CI, 1.617 to 31.314; p=0.009) during the follow-up period compared with the control group. Additionally, the IM group showed an increased rate of all-cause mortality (HR, 2.225; 95% CI, 1.858 to 2.663; p < 0.001).Conclusion This study suggests that individuals with a history of IM have an elevated risk of developing lymphoma and NPC in South Korea, emphasizing the importance of vigilant follow-up and monitoring. The results advocate for heightened awareness and potential national monitoring policies to address the long-term health implications of EBV infection and to implement preventive measures.